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Abstract A previous pilot study suggested that rizatrip-
tan reduces motion sickness induced by complex vestibular
stimulation. In this double-blind, randomized, placebo-
controlled study we measured motion sickness in response
to a complex vestibular stimulus following pretreatment
with either rizatriptan or a placebo. Subjects included 25
migraineurs with or without migraine-related dizziness
(23 females) aged 21–45 years (31.0 ± 7.8 years). Motion
sickness was induced by off-vertical axis rotation in
darkness, which stimulates both the semicircular canals and
otolith organs of the vestibular apparatus. Results indicated
that of the 15 subjects who experienced vestibular-induced
motion sickness when pretreated with placebo, 13 showed
a decrease in motion sickness following pretreatment with
rizatriptan as compared to pretreatment with placebo
(P\0.02). This signiﬁcant effect was not seen when
subjects were exposed to more provocative vestibular
stimulation. We conclude that the serotonin agonist, riza-
triptan, reduces vestibular-induced motion sickness by
inﬂuencing serotonergic vestibular-autonomic projections.
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Introduction
Motion sickness refers to a combination of autonomic and
cognitive symptoms and signs induced by exposure to
certain types of movement [1]. Although the deﬁnition of
motion sickness has been expanded to include stimuli
beyond pure vestibular stimulation, in the present study
motion sickness was induced by a complex vestibular
stimulation in darkness. The subjects in the present report
include individuals with migraine headache. Of note is that
some of the symptoms associated with migraine overlap
with symptoms of motion sickness such as upper abdom-
inal sensations, sleepiness, apathy, dizziness, cold sweat-
ing, increased salivation, pallor, and headache [2, 3]. It is
also notable that motion sickness occurs in approximately
50% of patients with migraine [4]. In this study, we only
included subjects who had both migraine and motion-
sickness susceptibility. The pathophysiologic basis for the
high incidence of motion sickness in migraine is unknown.
This lack of understanding, in part, motivated the present
study. Drummond [5] found that 30–40% of persons with
migraine report motion sickness with exposure to vestib-
ular stimulation and that motion-sickness susceptibility,
like migraine itself, is found more often in females [6].
Motion sickness can have a signiﬁcant negative impact
on an individual’s quality of life especially if the motion
sickness interferes with a person’s ability to get to and from
work, interferes with business travel, or interferes with
leisure activities.
The neurophysiologic basis of motion sickness is
unknown; however, several neurotransmitters seem to be
importantincludinghistamine,acetylcholine,noradrenaline,
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motionsicknessisbasedonclassesofmedicationthatcanbe
effective for treating motion sickness including antihista-
mines, scopolamine, amphetamines, and serotonin agonists
and antagonists [7–9]. Our recent pilot studies also suggest
that serotonin may be an important neurotransmitter in the
neural pathways that underlie motion sickness in that the
serotonin 1B/1D agonist, rizatriptan, appears to interfere
with the potentiation of visually induced motion sickness by
cranial pain [10].
The purpose of this study was to test the hypothesis that
serotonin agonists known to beneﬁt migraine headache also
reduce vestibular-induced motion sickness. For this study,
we selected subjects who had both migraine and motion-
sickness susceptibility. By addressing this hypothesis, we
aimed to elucidate the neural mechanisms underlying
motion sickness in humans. We also aimed to assess a
potential remedy for motion sickness in migraineurs with
high motion-sickness susceptibility.
Methods
Prior to initiating this double-blind, randomized, placebo-
controlled study, the protocol and consent form were
approved by the Institutional Review Board of the Uni-
versity of Pittsburgh. Advertisements were used to recruit
healthy adult migraineurs with a history of motion-sickness
susceptibility who had previously used triptans without
adverse effects. An informed consent was obtained from all
the subjects prior to enrollment.
Subjects
This study was designed to evaluate 25 subjects with
migraine with or without an additional diagnosis of
migraine-related dizziness [11, 12]. Eligible subjects
included healthy adult migraineurs aged 21–45 years who
had previously used and tolerated any triptan and who had
reported a history of motion sickness with either actual
motion or visually induced motion perception. A board-
certiﬁed neurologist conﬁrmed a diagnosis of migraine
based on IHS criteria [13]. All enrolled subjects were also
evaluated using the structured interview for migraine-
related dizziness [14, 15] and a clinical assessment based
on the criteria of Neuhauser et al. [11, 12]. Subjects were
excluded from the study if they were pregnant, had a his-
tory of cardiac disease, hypercholesterolemia, complicated
migraine, triptan intolerance, a family history of myocar-
dial infarction before age 45 in a ﬁrst-degree relative, a
weight greater than 250 lb, corrected vision worse than
20/40 OU, an active otologic disorder such as Meniere’s
disease, constant dizziness or vestibular symptoms, a pre-
viously identiﬁed vestibular abnormality such as benign
positional vertigo or an allergy or intolerance to gelatin.
Subjects using a beta-blocking agent or monamine oxidase
inhibitor in the past 2 weeks or who were using other
medications such as ergotamine were further excluded.
Additional exclusion criteria included clinically signiﬁcant
abnormalities on ocular-motor and vestibulo-ocular testing,
which was performed on a separate visit prior to random-
ization. Testing included video-oculographic recordings of
saccades, pursuit, and optokinetic nystagmus, a search for
positional, gaze-evoked, and spontaneous nystagmus, bin-
aural bithermal caloric testing, and earth-vertical axis
rotation. Audiometric testing was also performed. Standard
techniques were used and subjects were excluded based on
established normative data [16]. In order to enroll 26
subjects, 27 subjects underwent screening tests 1 of whom
was unable to complete the two experimental visits
described below because of elevated blood pressure while
receiving placebo. The 25 subjects who completed the
study consisted of 23 females and 2 males with an overall
age range of 21–45 years with an average age of
31.0 ± 7.8 years. Of these 25 subjects, 12 subjects met the
criteria for migraine-related dizziness (see Table 1).
Two experimental visits were scheduled for each sub-
ject. Each subject was randomized to receive a blinded
dose of the study drug, rizatriptan 10 mg, on their ﬁrst or
second visit and a placebo for the other visit. The subjects,
investigators, and technicians were all blinded to treatment
type. The rizatriptan and placebo were blinded in identical
capsules by a central pharmacy, which determined and
maintained the randomization assignment and labeled each
blinded medication with subject numbers. Subjects were
required to be headache-free and triptan-free for at least
1 week prior to each experimental visit. After receiving the
study drug or placebo, subjects were idle for 2 h during
which their blood pressure was monitored and adverse
events recorded. Then, each subject underwent a motion-
sickness provocation and assessment protocol.
The motion-sickness provocation and assessment pro-
tocol began with a baseline assessment of motion sickness
and subjective distress. Motion sickness was judged using
the motion-sickness scale developed by Graybiel [3],
which rates seven subjective and objective signs and
symptoms of motion sickness. Subjective units of distress
were rated 0–10 based on the method of Wolpe [17].
Subjects rated the severity of motion sickness and
subjective units of distress before and after each rotation. If
a subject reached a motion-sickness score of 16 or greater,
the experimental visit was terminated. Following the
baseline assessment, sinusoidal-earth–vertical earth axis
rotation in darkness at 0.05 Hz was performed to assess
post-drug/post-placebo vestibular-ocular reﬂex (VOR)
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123function, i.e. VOR gain and phase. The complex vestibular
stimulation to induce motion sickness consisted of off-
vertical axis rotation in darkness either in the clockwise or
counterclockwise direction at constant velocity. By using a
‘‘rotate, then tilt’’ paradigm [18] the stimulus primarily
activated the otolith organs of the inner ear and produced
motion sickness in susceptible subjects [19]. Off-vertical
axis rotation was continued for approximately 50 s. If the
subjects could tolerate additional stimulation, i.e. their
motion-sickness score was \16, following a 2 min rest,
they were then exposed to a second off-vertical axis rota-
tion in the direction opposite to that of the ﬁrst off-vertical
axis rotation. This second stimulus, in general, provokes
motion sickness in most subjects [18]. During both earth-
vertical and off-vertical axis rotations, eye movements
were recorded with electro-oculography.
Data analysis
Motion-sickness scores and subjective units of distress
were analyzed by computing the differences between
baseline (i.e. pre-earth-vertical axis rotation) and post-
stimulus values. Eye-movement data were analyzed using
standard techniques to compute gain and phase for
earth-vertical axis rotations and modulation and bias
components for off-vertical axis rotations [16]. At the
completion of this analysis, the data were unblinded. It
was determined that 10 of the 25 subjects developed
negligible motion sickness induced by the ﬁrst off-ver-
tical axis rotation following pre-medication with placebo.
The data from these subjects were not analyzed further.
Statistical analysis of the change in motion-sickness
scores was performed using a non-parametric paired
samples sign test under the null hypothesis that the
median baseline and post-stimulus scores are equal. The
number of subjects displaying a subjective improvement
in motion sickness was compared against the true value
(i.e. 8 of 15 subjects with improvement) that would be
expected if no rizatriptan treatment effect existed.
A one-tailed type I error rate of 0.05 was used to judge
the signiﬁcance of improvement in motion-sickness
scores.
Table 1 Subject Demographics
Subject number Age Gender Aura/no aura Migraine-related dizziness? Motion-sickness type Prior triptans used
1* 26 Female Aura Yes Vestibular, visual Rizatriptan, sumatriptan
2 33 Female Aura No Visual Eletriptan
3* 26 Female Aura Yes Vestibular Eletriptan, rizatriptan, sumatriptan
4 26 Male No aura Yes Vestibular, visual Rizatriptan, sumatriptan
5* 45 Female No aura No Vestibular Sumatriptan
6* 25 Female Aura Yes Vestibular, visual Sumatriptan
7* 40 Female No aura No Vestibular Eletriptan, rizatriptan, sumatriptan
8* 21 Female Aura Yes Visual Sumatriptan
9 25 Female No aura No Vestibular, visual Sumatriptan
10* 22 Female No aura Yes Vestibular, visual Sumatriptan
11* 24 Female No aura Yes Vestibular Sumatriptan
12* 28 Female Aura Yes Vestibular Sumatriptan
13* 31 Female Aura No Vestibular Naratriptan
14 30 Female Aura Yes Vestibular, visual Sumatriptan
15 27 Female Aura No Vestibular Rizatriptan, sumatriptan
16* 41 Female Aura Yes Vestibular, visual Sumatriptan
17 24 Female Aura No Vestibular Sumatriptan
18 25 Female Aura Yes Vestibular Frovatriptan
19* 41 Male No aura Yes Vestibular Sumatriptan
20 25 Female No aura No Vestibular, visual Sumatriptan
21* 42 Female No aura No Vestibular, visual Sumatriptan
22 26 Female No aura No Vestibular, visual Eletriptan, sumatriptan
23* 40 Female No aura No Vestibular, visual Rizatriptan, sumatriptan
24 41 Female Aura No Vestibular Rizatriptan, sumatriptan
25* 42 Female Aura No Visual Rizatriptan, sumatriptan
* Included for statistical analysis
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All 25 subjects who completed the study could undergo at
least one off-vertical rotation at each of the two visits. Three
subjectshadmotion-sicknessscoresof16orgreaterfollowing
the ﬁrstoff-verticalaxisrotation duringone orbothvisits and
thus could not undergo a second off-vertical axis rotation on
that visit. For one of these subjects, this occurred only during
the placebo visit; for two of these subjects, this occurred only
during the rizatriptan visit. Motion-sickness scores following
the ﬁrst off-vertical axis rotation referenced to baseline
motion-sicknessscoreareshowninFig. 1a.Notethatthedata
are shown only for 15 of the 25 subjects, namely, those sub-
jects who experienced a motion-sickness score that was more
than 3 points higher than baseline following their ﬁrst off-
vertical axis rotation on the experimental visit during which
they received placebo. Note that 13 of these 15 subjects
experienced decreased motion sickness with rizatriptan as
comparedtoplacebo,which isa statisticallysigniﬁcantresult
(P\0.02,signtest,one-tailed).Notefurtherthatthestatusof
the patients regarding the presence or absence of a history of
migraine-related dizziness did not appear to inﬂuence the
effect of rizatriptan. When these same individuals were
exposed to a second off-vertical axis rotation, there was no
apparent beneﬁt from rizatriptan regarding motion-sickness
score referenced to baseline motion sickness (Fig. 1b).
Although there was no signiﬁcant effect of rizatriptan on
motion-sickness score following the second off-vertical axis
rotation, there was a trend for subjects without migraine-
related dizziness to show a beneﬁt with rizatriptan as com-
pared to placebo (4 of 5 subjects). A further analysis of
motion-sickness score was performed using the ten subjects
whodidnotachievesigniﬁcantmotionsicknessfollowingthe
ﬁrst off-vertical axis rotation on the experimental visit during
which they received placebo. Of these ten individuals, three
individualsexperiencedsigniﬁcantmotionsicknessfollowing
the second off-vertical axis rotation on the experimental visit
duringwhichtheyreceivedplacebo.Twooftheseindividuals
experienced more motion sickness following the second off-
vertical axis rotation on the visit during which they received
rizatriptan.Ananalysisofsubjectiveunitsofdistressindicated
that there was no apparent difference between the effects of
rizatriptan and placebo (See Fig. 2).
Eye-movement parameters were analyzed for evidence
of a consistent effect of rizatriptan on the VOR or a cor-
relation between motion sickness and the VOR. No con-
sistent effects were found.
Discussion
The results of this study corroborate the implications of our
prior pilot study, which suggested that rizatriptan provided
protection against motion sickness induced by complex
vestibular stimulation in migraineurs [20]. In the present
study, which also assessed migraineurs with a history of
motion sickness, an additional diagnosis of migraine-rela-
ted dizziness did not affect outcome aside from a trend
toward a protective effect of rizatriptan in subjects without
Fig. 1 a Motion-sickness score following pretreatment with rizatrip-
tan vs. motion-sickness score following pretreatment with placebo in
response to a complex vestibular stimulus, i.e. off-vertical axis
rotation. Scores represent the increase in motion sickness above pre-
stimulus baseline. Note that data are shown only from those subjects
whose vestibular-induced increase in motion-sickness score exceeded
3 after pretreatment with placebo. Data from subjects with migraine-
related dizziness are shown as ﬁlled circles. Data from subjects
without migraine-related dizziness are shown as open circles. Note
that for 13 of 15 subjects that the increase in motion-sickness score
above baseline was greater following pretreatment with placebo as
compared to that seen following treatment with rizatriptan. b Motion-
sickness scores following a second off-vertical axis rotation. Data are
shown for those subjects who could complete a second off-vertical
axis rotation following pretreatment with rizatriptan and following
pretreatment with placebo. Note the lack of an obvious effect of
rizatriptan
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axis rotation. Possibly, a protective effect was found in
subjects with and without migraine-related dizziness
because all subjects were individuals with motion-sickness
susceptibility. The lack of an effect of pretreatment of
rizatriptan on motion sickness in response to a second off-
vertical axis rotation suggests a type of dose–response
mechanism in that rizatriptan at a single dose provided
protection for a lower level of stimulation but not a higher
level of motion-sickness provocation. The trend for sub-
jects without migraine-related dizziness to gain beneﬁt
from rizatriptan despite a high level of motion-sickness
provocation suggests that subjects with migraine-related
dizziness may be more susceptible to motion sickness [21,
22]. Our results suggest that rizatriptan may increase the
threshold for producing motion sickness. The second off-
vertical axis rotation may have been a suprathreshold
stimulus despite rizatriptan, especially in subjects with
migraine-related dizziness. This concept is consistent with
the recent suggestion that motion-sickness susceptibility
and migraine may be related to an innate vestibular hyper-
sensitivity [23] and the expression of 5-HT1B and 5-HT1D
receptor targets of triptans by most vestibular ganglion
cells [24].
Our study also suggests that rizatriptan did not increase
subjective units of discomfort. The side effects of riza-
triptan can include fatigue, somnolence, head and neck
pressure, nonspeciﬁc dizziness, and nausea, and thus might
have been expected to increase subjective units of dis-
comfort despite its beneﬁt for reduction of motion sickness.
Evidently, the level of distress caused by side effects of
rizatriptan was offset by the reduction in motion sickness
following pretreatment with rizatriptan. We speculate that
the effect of rizatriptan was mediated via its effects on
vestibulo-autonomic rather than vestibulo-ocular pathways.
Our prior study of rizatriptan suggested that the eye-
movement response during off-vertical axis rotation was
inﬂuenced by pretreatment with rizatriptan. Speciﬁcally,
our study suggested that the bias component of the eye-
movement response to off-vertical axis rotation was
reduced following pretreatment with rizatriptan. The cur-
rent study does not support this ﬁnding in a larger group of
subjects. In that the bias component reﬂects central nervous
system processing of peripheral vestibular activity, the
absence of a reduction in the magnitude of the bias com-
ponent suggests that rizatriptan does not interfere with the
so called ‘‘velocity storage system’’ of central vestibulo-
ocular processing. In addition, there were no consistent
changes in VOR gain and phase following pretreatment
with rizatriptan. This further suggests that the effect of
rizatriptan on motion sickness is not mediated via changes
in ‘‘velocity storage.’’
The present study has implications for understanding
the pathophysiology of migraine-related dizziness and
motion sickness in migraineurs. Recent studies indicate a
remarkable degree of neurochemical similarity between
nociceptive trigeminal ganglion cells and vestibular gan-
glion cells. For example, most vestibular ganglion cells
express functional biomarkers associated with nociception,
such as TRPV1 receptors [25], substance P [26], P2X3
purinergic receptors [27], and both the 5-HT1B and 5-HT1D
receptors [24]. Moreover, plasma extravasation occurs in
the vestibular periphery at the same time as extravasation
in the meninges in a murine model of neurogenic migraine
[28]. Finally, functional imaging studies report that
increased cerebral blood ﬂow in a region of the dorsal and
dorsolateral pons accompanies both spontaneous and
glyceryl trinitrate induced migraine attacks [29–33]; the
implicated region appears to include portions of the ves-
tibular nuclei, medial parabrachial nucleus, locus coeruleus
and dorsal raphe nuclei.
Thereisalsoaconsiderableoverlapofsymptomsbetween
motion sickness and migraine. Motion sickness describes a
progressionofsymptomsevokedbyrealorvirtualmotion.It
begins with the ‘sopite syndrome’ [34], a form of motion
sickness that is characterized by yawning, drowsiness, dis-
inclination for either physical or mental work, and lack of
participationingroupactivities.Thesymptomscanprogress
tovagueabdominaldiscomfort,hyperventilation,salivation,
pallor, profuse cold sweating, somnolence, and nausea.
Vomiting and retching can also ensue. There is a striking
overlap with symptoms of migraine and passive emotional
coping responses to pain [35, 36]. Hence, the efﬁcacy of
rizatriptan against motion sickness is consistent with the
hypothesis that engagement of migraine-related mecha-
nisms, such as trigemino-vascular reﬂexes and central pain
Fig. 2 Subjective units of distress after off-vertical axis rotation
following pretreatment with rizatriptan vs. placebo. Note that data are
shown for those subjects whose data are illustrated in Fig. 1. Note the
absence of a consistent inﬂuence of rizatriptan
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123pathways, may contribute to the generation of motion
sickness.
As summarized in Fig. 3, the enhanced motion-sickness
susceptibility in migraineurs may be a function of the net
vestibular nuclear and solitary nucleus effects of vestibular
stimulation. Triptans have been shown to reduce nocicep-
tive activation in animal studies through actions on
somatic, vascular and dural afferents, and central trigemi-
nal and solitary nucleus neurons [37–40]. These actions
appear to be primarily by 5-HT1B and 5-HT1D-mediated
presynaptic inhibition [40, 41]. Activation of 5-HT1B and
5-HT1D receptors in the ventrolateral periaqueductal
gray inhibit trigeminal and solitary nucleus nociceptive
responses [42] and affect passive coping responses to pain
[36] that resemble the prodromal features of motion sick-
ness. We propose that motion-sickness sensitivity is
decreased by the additional actions of rizatriptan on
5-HT1B and 5-HT1D receptors on vestibular ganglion cells
[24] and vestibular nuclear neurons [43], which would be
expected to raise the threshold for eliciting symptoms.
Rizatriptan can also have direct vascular effects via 5-HT1B
and 5-HT1D receptors, attenuating vasodilatation and
extravasation from cerebral and inner ear vasculature.
Thus, these ﬁndings are consistent with the concept that
parallel activation of vestibular and cranial nociceptive
pathways may contribute to the otologic features of
migraine-related dizziness. More generally, they provide a
basis for an emerging view that motion sickness may be a
form of interoceptive pain.
At present, there are several symptomatic treatments for
motion sickness including vestibular suppressant medica-
tions such as meclizine. Individuals especially prone to
Fig. 3 Schematic diagram to explain effects of rizatriptan on motion
sickness in migraineurs. The enhanced motion-sickness susceptibility
in migraineurs is hypothesized to reﬂect the net vestibular nuclear and
solitary nucleus effects of vestibular stimulation. The trigeminal
nociceptive pathway and vestibular nuclei also contribute ascending
thalamic connections, which contribute to autonomic symptoms via
projections to the cerebral cortex. Spinal trigeminal nuclear and
vestibular nuclear neurons also project to the parabrachial nucleus.
Stress responses and vasopressin release are mediated by intercon-
nections of the parabrachial pathways with the hypothalamus. We
propose that motion-sickness sensitivity is decreased by the actions of
rizatriptan on 5-HT1B and 5-HT1D receptors on (1) vasculature (e.g.
blocking vasodilatation), (2) vestibular ganglion cells, (3) trigeminal
ganglion cells (for somatic, vascular and dural afferents), (4) several
brainstem pathways and projections, and (5) neurons in the periaqu-
eductal gray (PAG). The primary effect of rizatriptan is via
presynaptic inhibition of terminals that can use either excitatory
amino acids or GABA. These presynaptic effects can occur at primary
afferent and in CNS pathways
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123motion sickness often avoid provocative activities. Pre-
ventive treatments include scopolamine, promethazine, and
antihistamines. These medications usually cause sedation
or other unwanted effects.
The reduction in motion sickness following pretreat-
ment with rizatriptan suggests that rizatriptan may pro-
vide beneﬁt for migraineurs who suffer from motion
sickness. As noted above, the mechanism whereby riza-
triptan reduces motion sickness may be related to an
alteration in the threshold for motion sickness based on
serotonergic mechanisms. Of interest is that no changes
in the VOR were found in response to rizatriptan despite
effects on motion sickness. This ﬁnding does not support
the current theories of motion sickness proffered by Dai
et al. [44] and studied by Jeong et al. [23] that so called
‘‘velocity storage’’ in the VOR is fundamental to motion
sickness. Possibly, migraineurs who cannot avoid motion
sickness provoking environments could pre-medicate
with rizatriptan with beneﬁt. Further research would be
required to establish this potential beneﬁt in that the
present study is laboratory-based and may not entirely
reﬂect the level of symptoms produced in a natural
environment.
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